Clinical Trial

Evaluation of the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation

Study acronym: NOVACC
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 22, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double blind, multicenter study following surgery with extracorporeal circulation to compare blood pressure optimization with vasopressin versus noradrenaline. It is planned to include 840 patients in order to have 420 patients with vasoplegic syndrome. The primary objective of this study is to determine whether the use of vasopressin to maintain blood pressure following cardiac surgery decreases the number of patients with acute renal failure and/or death compared with the usual use of norepinephrine. Participation in the study involves daily follow-up at D1, D2, and D7 of the onset of the syndrome and then follow-up at D30 and D90.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-10-03; most recent amendment 2025-12-16.
Status change: Recruiting → Active, Not Recruiting 2025-12-16
Status change: Not Yet Recruiting → Recruiting 2023-01-04
Trial Details
NCT Number NCT05568160
Lead Sponsor Centre Hospitalier Universitaire Dijon
Conditions Scheduled Cardiac Surgery With Extracorporeal Circulation, Vasoplegic Syndrome
Enrollment 840 participants
Start Date 2023-01-02
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-12-22